Progress on the study of the anticancer effects of artesunate (Review)
- Authors:
- Xiulan Yang
- Yudong Zheng
- Lian Liu
- Jiangrong Huang
- Fei Wang
- Jie Zhang
-
Affiliations: Department of Pharmacology, The School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China, Department of Pharmacology, The School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China, Center of Experiment and Training, Hubei College of Chinese Medicine, Jingzhou, Hubei 434020, P.R. China - Published online on: August 27, 2021 https://doi.org/10.3892/ol.2021.13011
- Article Number: 750
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A and Siegel RL: Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 70:443–459. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa C, Senba M and Mori N: Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. Eur J Pharmacol. 872:1729532020. View Article : Google Scholar : PubMed/NCBI | |
|
Slezakova S and Ruda-Kucerova J: Anticancer activity of artemisinin and its derivatives. Anticancer Res. 37:5995–6003. 2017.PubMed/NCBI | |
|
Cen YY, Zao YB, Li P, Li XL, Zeng XX and Zhou H: Research progress on pharmacokinetics and pharmacological activities of artesunate. Zhongguo Zhong Yao Za Zhi. 43:3970–3978. 2018.(In Chinese). PubMed/NCBI | |
|
Khanal P: Antimalarial and anticancer properties of artesunate and other artemisinins: Current development. Monatsh Chem. Mar 30–2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Chen Y, Wang F, Wu H, Zhang Y, Liu J, Cai Y, Huang S, He N, Hu Z and Jin X: Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. Chem Biol Interact. 331:1092732020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao F, Vakhrusheva O, Markowitsch SD, Slade KS, Tsaur I, Cinatl J Jr, Michaelis M, Efferth T, Haferkamp A and Juengel E: Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction. Cells. 9:26432020. View Article : Google Scholar : PubMed/NCBI | |
|
Markowitsch SD, Schupp P, Lauckner J, Vakhrusheva O, Slade KS, Mager R, Efferth T, Haferkamp A and Juengel E: Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers (Basel). 12:31502020. View Article : Google Scholar : PubMed/NCBI | |
|
Klaunig JE: Oxidative stress and cancer. Curr Pharm Des. 24:4771–4778. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lichota A and Gwozdzinski K: Anticancer activity of natural compounds from plant and marine environment. Int J Mol Sci. 19:35332018. View Article : Google Scholar : PubMed/NCBI | |
|
Chekem L and Wierucki S: Extraction of artemisinin and synthesis of its derivates artesunate and artemether. Med Trop (Mars). 66:602–605. 2006.(In French). PubMed/NCBI | |
|
Efferth T: From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 46:65–83. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wei T and Liu J: Anti-angiogenic properties of artemisinin derivatives (review). Int J Mol Med. 40:972–978. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ho WE, Peh HY, Chan TK and Wong WS: Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther. 142:126–139. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Sun X, Wang L, Wong YK, Lee YM, Zhou C, Wu G, Zhao T, Yang L, Lu L, et al: Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 19:263–273. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Alagbonsi AI, Salman TM, Sulaiman SO, Adedini KA and Kebu S: Possible mechanisms of the hypoglycaemic effect of artesunate: Gender implication. Metabol Open. 10:1000872021. View Article : Google Scholar : PubMed/NCBI | |
|
Venturini E, Zammarchi L, Bianchi L, Montagnani C, Tersigni C, Bortone B, Chiappini E and Galli L: Efficacy and safety of intravenous artesunate in children with severe imported malaria. Pediatr Infect Dis J. 39:e2202020. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Shi X, Liu J, Shao F, Huang G, Zhou Z and Zheng P: Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL-4-producing T cells and regulatory T cells. FASEB J. 33:8241–8248. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Xu K, Pian G and Sun S: Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth. Oncol Lett. 18:4735–4743. 2019.PubMed/NCBI | |
|
Pirali M, Taheri M, Zarei S, Majidi M and Ghafouri H: Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells. Int J Biol Macromol. 164:3369–3375. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wang Q, He T, Li W, Liu Y, Fan Y, Wang Y, Wang Q and Chen J: The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer. Clin Exp Pharmacol Physiol. 47:1083–1091. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Liu J and Liu L: Artesunate inhibits lung cancer cells via regulation of mitochondrial membrane potential and induction of apoptosis. Mol Med Rep. 22:3017–3022. 2020.PubMed/NCBI | |
|
Zhang Q, Yi H, Yao H, Lu L, He G, Wu M, Zheng C, Li Y, Chen S, Li L, et al: Artemisinin derivatives inhibit non-small cell lung cancer cells through induction of ROS-dependent apoptosis/ferroptosis. J Cancer. 12:4075–4085. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Verma S, Das P and Kumar VL: Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of β-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis. Chem Biol Interact. 278:84–91. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ma JD, Jing J, Wang JW, Yan T, Li QH, Mo YQ, Zheng DH, Gao JL, Nguyen KA and Dai L: A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Res Ther. 21:1532019. View Article : Google Scholar : PubMed/NCBI | |
|
Qian P, Zhang YW, Zhou ZH, Liu JQ, Yue SY, Guo XL, Sun LQ, Lv XT and Chen JQ: Artesunate enhances γδ T-cell-mediated antitumor activity through augmenting γδ T-cell function and reversing immune escape of HepG2 cells. Immunopharmacol Immunotoxicol. 40:107–116. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jing W, Shuo L, Yingru X, Min M, Runpeng Z, Jun X and Dong H: Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochem Biophys Res Commun. 519:41–45. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
He W, Huang X, Berges BK, Wang Y, An N, Su R and Lu Y: Artesunate regulates neurite outgrowth inhibitor protein B receptor to overcome resistance to sorafenib in hepatocellular carcinoma cells. Front Pharmacol. 12:6158892021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Lai Y and Hua ZC: Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci Rep. 39:BSR201809922019. View Article : Google Scholar : PubMed/NCBI | |
|
Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, Shen HM and Wang J: Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. Med Res Rev. 37:1492–1517. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Gan S, Han L, Li X, Xie X, Zou D and Sun H: Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia. Ann Transl Med. 8:7672020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhang XL, Zhang GH and Gao YF: Artesunate promotes Th1 differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via miR-142. Braz J Med Biol Res. 52:e79922019. View Article : Google Scholar : PubMed/NCBI | |
|
Peng J, Yuan C, Wu Z, Wang Y, Yin W, Lin Y, Zhou L and Lu J: Upregulation of microRNA-1 inhibits proliferation and metastasis of breast cancer. Mol Med Rep. 22:454–464. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zhou L, Xiang JD, Jin CS, Li MQ and He YY: Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT. Int Immunopharmacol. 97:1077052021. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes JD, Dinkova-Kostova AT and Tew KD: Oxidative stress in cancer. Cancer Cell. 38:167–197. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kohan R, Collin A, Guizzardi S, Tolosa de Talamoni N and Picotto G: Reactive oxygen species in cancer: A paradox between pro- and anti-tumour activities. Cancer Chemother Pharmacol. 86:1–13. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kirtonia A, Sethi G and Garg M: The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 77:4459–4483. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Srinivas US, Tan BWQ, Vellayappan BA and Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox Biol. 25:1010842019. View Article : Google Scholar : PubMed/NCBI | |
|
Fei Z, Gu W, Xie R, Su H and Jiang Y: Artesunate enhances radiosensitivity of esophageal cancer cells by inhibiting the repair of DNA damage. J Pharmacol Sci. 138:131–137. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Petricciuolo M, Davidescu M, Fettucciari K, Gatticchi L, Brancorsini S, Roberti R, Corazzi L and Macchioni L: The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells. Heliyon. 6:e057412020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Wang X, Wang X, Zhou Y, Li Y, Wang A, Wang T, An Y, Sun W, Du J, et al: TEOA inhibits proliferation and induces DNA damage of diffuse large b-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway. Front Pharmacol. 11:5547362020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Li M, Zhu X, Zhang Z, Huang H and Hou L: Artemisinin co-delivery system based on manganese oxide for precise diagnosis and treatment of breast cancer. Nanotechnology. Apr 28–2021.(Epub ahead of print). | |
|
Yao X, Zhao CR, Yin H, Wang K and Gao JJ: Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. Acta Pharmacol Sin. 41:1609–1620. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Viallard C and Larrivée B: Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic cancer: Current research status and clinical implications. Angiogenesis. 22:15–36. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G, He Y, Li Y, Zheng L, Zhang Q, et al: Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/BAI1 signaling pathway. Angiogenesis. 23:325–338. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Singh N, Badrun D and Ghatage P: State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. Expert Opin Pharmacother. 21:1579–1590. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Shi L, Yang X, Li S, Guo X and Pan L: Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol. 92:587–597. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Andrade-Tomaz M, de Souza I, Rocha CRR and Gomes LR: The role of chaperone-mediated autophagy in cell cycle control and its implications in cancer. Cells. 9:21402020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Shou LM, Lin F, Duan WM, Wu MY, Xie X, Xie YF, Li W and Tao M: Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer Drugs. 25:652–662. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weng X, Zhu SQ and Cui HJ: Artesunate inhibits proliferation of glioblastoma cells by arresting cell cycle. Zhongguo Zhong Yao Za Zhi. 43:772–778. 2018.(In Chinese). PubMed/NCBI | |
|
Wang Y, Wei Z, Pan K, Li J and Chen Q: The function and mechanism of ferroptosis in cancer. Apoptosis. 25:786–798. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H, et al: Systematic analysis of the aberrances and functional implications of ferroptosis in cancer. iScience. 23:1013022020. View Article : Google Scholar : PubMed/NCBI | |
|
Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, et al: Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin. 42:301–310. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hu LJ, Jiang T, Wang FJ, Huang SH, Cheng XM and Jia YQ: Effects of artesunate combined with bortezomib on apoptosis and autophagy of acute myeloid leukemia cells in vitro and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 40:204–208. 2019.(In Chinese). PubMed/NCBI | |
|
Kim C, Lee JH, Kim SH, Sethi G and Ahn KS: Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model. Oncotarget. 6:4020–4035. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC and Pullarkat V: Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. Leuk Res. 59:124–135. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Du Q, Mao Z, Fan X, Hu B, Wang Z, Chen Z, Jiang X, Wang Z, Lei N, et al: Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines. Oncotarget. 8:45874–45887. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, Debatin KM and Halatsch ME: Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anticancer Agents Med Chem. 14:313–318. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Berte N, Lokan S, Eich M, Kim E and Kaina B: Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence. Oncotarget. 7:67235–67250. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lian S, Shi R, Huang X, Hu X, Song B, Bai Y, Yang B, Dong J, Du Z, Zhang Y, et al: Artesunate attenuates glioma proliferation, migration and invasion by affecting cellular mechanical properties. Oncol Rep. 36:984–990. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Berdelle N, Nikolova T, Quiros S, Efferth T and Kaina B: Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther. 10:2224–2233. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO and Luo S: Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis. 5:e14662014. View Article : Google Scholar : PubMed/NCBI | |
|
Wei S, Liu L, Chen Z, Yin W, Liu Y, Ouyang Q, Zeng F, Nie Y and Chen T: Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence. J Cell Mol Med. 24:276–284. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Greenshields AL, Fernando W and Hoskin DW: The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 107:10–22. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wen L, Liu L, Wen L, Yu T and Wei F: Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation. Breast Cancer. 25:681–686. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Greenshields AL, Shepherd TG and Hoskin DW: Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 56:75–93. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Bu S, Sun J, Guo Y and Lai D: Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim Biophys Sin (Shanghai). 50:1227–1235. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Zuo LF, Zuo J and Wang J: Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo. Mol Med Rep. 12:1465–1472. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Liu L, Chen Y, Du Y, Wang J and Liu J: Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate. Pathol Res Pract. 214:1467–1473. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Liu L, Wang J and Chen Y: Inhibitory effect of artesunate on growth and apoptosis of gastric cancer cells. Arch Med Res. 48:623–630. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Luo HS, Li M and Tan SY: Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Onco Targets Ther. 8:845–854. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang F, Zhou JY, Zhang D, Liu MH and Chen YG: Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate-induced apoptosis. Int J Mol Med. 42:1295–1304. 2018.PubMed/NCBI | |
|
Kumar VL, Verma S and Das P: Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer. Drug Dev Res. 80:1089–1097. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ilamathi M, Santhosh S and Sivaramakrishnan V: Artesunate as an anti-cancer agent targets stat-3 and favorably suppresses hepatocellular carcinoma. Curr Top Med Chem. 16:2453–2463. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wojcicki AV, Kasowski MM, Sakamoto KM and Lacayo N: Metabolomics in acute myeloid leukemia. Mol Genet Metab. 130:230–238. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Efferth T, Giaisi M, Merling A, Krammer PH and Li-Weber M: Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One. 2:e6932007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yang J, Chen L, Wang J, Wang Y, Luo J, Pan L and Zhang X: Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells. Chem Biol Interact. 219:28–36. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tan M, Rong Y, Su Q and Chen Y: Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells. Leuk Res. 62:98–103. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Feng L, Li Y, Jiang W, Shan N and Wang X: Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide. Leuk Lymphoma. 55:1366–1372. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J and Heuck C: Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget. 5:4118–4128. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Blessing MM and Alexandrescu S: Embryonal tumors of the central nervous system: An update. Surg Pathol Clin. 13:235–247. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alegría-Loyola MA, Galnares-Olalde JA and Mercado M: Tumors of the central nervous system. Rev Med Inst Mex Seguro Soc. 55:330–340. 2017.(In Spanish). PubMed/NCBI | |
|
Francis SS, Wang R, Enders C, Prado I, Wiemels JL, Ma X and Metayer C: Socioeconomic status and childhood central nervous system tumors in California. Cancer Causes Control. 32:27–39. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rödel C and Rödel F: A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol. 103:394–401. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi D, Hirayama M, Komohara Y, Mizuguchi S, Wilson Morifuji M, Ihn H, Takeya M, Kuramochi A and Araki N: Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors. J Biol Chem. 289:26314–26326. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Wen J, Wang S, Yao J, Liao L and Dong J: Association between adipokines and thyroid carcinoma: A meta-analysis of case-control studies. BMC Cancer. 20:7882020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L and Fei H: Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism. J Bioenerg Biomembr. 52:123–130. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, et al: PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 38:2620–2627. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Breast Cancer Expert Committee of National Cancer Quality Control Center; Breast Cancer Expert Committee of China Anti-Cancer Association; Cancer Drug Clinical Research Committee of China Anti-Cancer Association, . Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 edition). Zhonghua Zhong Liu Za Zhi. 42:781–797. 2020.(In Chinese). PubMed/NCBI | |
|
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and Farahmand L: Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI | |
|
Britt KL, Cuzick J and Phillips KA: Key steps for effective breast cancer prevention. Nat Rev Cancer. 20:417–436. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P and Li Y: Exosomes and breast cancer drug resistance. Cell Death Dis. 11:9872020. View Article : Google Scholar : PubMed/NCBI | |
|
Tran TH, Nguyen TD, Poudel BK, Nguyen HT, Kim JO, Yong CS and Nguyen CN: Development and evaluation of artesunate-loaded chitosan-coated lipid nanocapsule as a potential drug delivery system against breast cancer. AAPS PharmSciTech. 16:1307–1316. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tran TH, Nguyen AN, Kim JO, Yong CS and Nguyen CN: Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers. Artif Cells Nanomed Biotechnol. 44:1979–1987. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Yuan H, Guo Y, Wang K, Wang X and Guo Z: Towards rational design of RAD51-targeting prodrugs: platinumIV-artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells. Chem Commun (Camb). 54:11717–11720. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Raza A, Ghoshal A, Chockalingam S and Ghosh SS: Connexin-43 enhances tumor suppressing activity of artesunate via gap junction-dependent as well as independent pathways in human breast cancer cells. Sci Rep. 7:75802017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Zhu YT, Xiang M, Qiu JL, Luo SQ and Lin F: Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: Reversed by artesunate. Acta Pharmacol Sin. 42:624–632. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kujawa KA and Lisowska KM: Ovarian cancer-from biology to clinic. Postepy Hig Med Dosw (Online). 69:1275–1290. 2015.(In Polish). View Article : Google Scholar : PubMed/NCBI | |
|
Aziz NB, Mahmudunnabi RG, Umer M, Sharma S, Rashid MA, Alhamhoom Y, Shim YB, Salomon C and Shiddiky MJA: MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors. Analyst. 145:2038–2057. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gaona-Luviano P, Medina-Gaona LA and Magaña-Pérez K: Epidemiology of ovarian cancer. Chin Clin Oncol. 9:472020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Qi S, Shi C, Han X, Yu J, Zhang L, Qin S and Gao Y: Identification of metastasis and prognosis-associated genes for serous ovarian cancer. Biosci Rep. 40:BSR201943242020. View Article : Google Scholar : PubMed/NCBI | |
|
Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI | |
|
Rooth C: Ovarian cancer: Risk factors, treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA III, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, et al: Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial. J Clin Oncol. 38:1164–1174. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yadav G, Vashisht M, Yadav V and Shyam R: Molecular biomarkers for early detection and prevention of ovarian cancer-a gateway for good prognosis: A narrative review. Int J Prev Med. 11:1352020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HH, Zhou HJ, Wu GD and Lou XE: Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 71:1–9. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Hou D, Liu Q, Wu T, Guo H, Zhang X, Zou Y, Liu Z, Liu J, Wei J, et al: Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther. 16:1548–1556. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fatehi Hassanabad A, Chehade R, Breadner D and Raphael J: Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr). 43:195–209. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fan J, Liu Z, Mao X, Tong X, Zhang T, Suo C and Chen X: Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017. Cancer Med. 9:6875–6887. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi R, Cui H, Bi Y, Huang X, Song B, Cheng C, Zhang L, Liu J, He C, Wang F, et al: Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma. Oncol Lett. 9:2249–2255. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Eusebi LH, Telese A, Marasco G, Bazzoli F and Zagari RM: Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol. 35:1495–1502. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Niu PH, Zhao LL, Wu HL, Zhao DB and Chen YT: Artificial intelligence in gastric cancer: Application and future perspectives. World J Gastroenterol. 26:5408–5419. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Sun WJ, Wang WM, Chen K, Zheng JH, Lu MD, Li PH and Zheng ZQ: Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs. 24:920–927. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Su T, Li F, Guan J, Liu L, Huang P, Wang Y, Qi X, Liu Z, Lu L and Wang D: Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling. Phytomedicine. 63:1529682019. View Article : Google Scholar : PubMed/NCBI | |
|
La Vecchia S and Sebastián C: Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 98:63–70. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Johdi NA and Sukor NF: Colorectal cancer immunotherapy: Options and strategies. Front Immunol. 11:16242020. View Article : Google Scholar : PubMed/NCBI | |
|
Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L and Sun ZX: Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer. 121:1360–1365. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu J, Han Z, Fu J, Fu Z and Tong H: Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. Int Immunopharmacol. 27:110–121. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bei Y, Chen X, Raturi VP, Liu K, Ye S, Xu Q and Lu M: Treatment patterns and outcomes change in early-stage non-small cell lung cancer in octogenarians and older: A SEER database analysis. Aging Clin Exp Res. 33:147–156. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huo KG, D'Arcangelo E and Tsao MS: Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Transl Lung Cancer Res. 9:2214–2232. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu K, Zhang C, Du T, Gabriel ANA, Wang X, Li X, Sun L, Wang N, Jiang X and Zhang Y: Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 134:1111112021. View Article : Google Scholar : PubMed/NCBI | |
|
Rasheed SA, Efferth T, Asangani IA and Allgayer H: First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127:1475–1485. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Jiang W, Li B, Yao Q, Dong J, Cen Y, Pan X, Li J, Zheng J, Pang X and Zhou H: Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol. 11:2039–2046. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JS, Wang MJ, Lu X, Zhang J, Liu QX, Zhou D, Dai JG and Zheng H: Artesunate inhibits epithelial-mesenchymal transition in non-small-cell lung cancer (NSCLC) cells by down-regulating the expression of BTBD7. Bioengineered. 11:1197–1207. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Han K, Chen F, Wu C and Huang W: Effects of artesunate on the invasion of lung adenocarcinoma A549 cells and expression of ICAM-1 and MMP-9. Zhongguo Fei Ai Za Zhi. 16:567–571. 2013.(In Chinese). PubMed/NCBI | |
|
Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget. 7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Ma G, Deng Y, Wu Q, Wang Z and Zhou Q: Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhibiting MAPK pathway. Gene. 766:1451342021. View Article : Google Scholar : PubMed/NCBI | |
|
Anwanwan D, Singh SK, Singh S, Saikam V and Singh R: Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Z, Wei-Qi J and Jin D: New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 1874:1883822020. View Article : Google Scholar : PubMed/NCBI | |
|
Hou J, Wang D, Zhang R and Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res. 14:5519–5530. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jin M, Shen X, Zhao C, Qin X, Liu H, Huang L, Qiu Z and Liu Y: In vivo study of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice. Drug Deliv. 20:127–133. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guragain D, Seubwai W, Kobayashi D, Silsinivanit A, Vaeteewoottacharn K, Sawanyawisuth K, Wongkham C, Wongkham S, Araki N and Cha'on U: Artesunate and chloroquine induce cytotoxic activity on cholangiocarcinoma cells via different cell death mechanisms. Cell Mol Biol (Noisy-le-grand). 64:113–118. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang ZC, Liu Y, Wang H, Han QK and Lu C: Research on the relationship between artesunate and raji cell autophagy and apoptosis of burkitt's lymphoma and its mechanism. Eur Rev Med Pharmacol Sci. 21:2238–2243. 2017.PubMed/NCBI | |
|
Chauhan AK, Min KJ and Kwon TK: RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma caki cells. Mol Cell Biochem. 435:15–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sarma B, Willmes C, Angerer L, Adam C, Becker JC, Kervarrec T, Schrama D and Houben R: Artesunate affects T antigen expression and survival of virus-positive merkel cell carcinoma. Cancers (Basel). 12:9192020. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng L and Pan J: The anti-malarial drug artesunate blocks Wnt/β-catenin pathway and inhibits growth, migration and invasion of uveal melanoma cells. Curr Cancer Drug Targets. 18:988–998. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wang C, Wu Z, Xue J, Shen B, Zuo W, Wang Z and Wang SL: Artesunate suppresses the growth of prostatic cancer cells through inhibiting androgen receptor. Biol Pharm Bull. 40:479–485. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Wu N, Wu Y, Chen H, Qiu J, Qian X, Zeng J, Chiu K, Gao Q and Zhuang J: Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6. Cell Death Dis. 10:8622019. View Article : Google Scholar : PubMed/NCBI | |
|
Roh JL, Kim EH, Jang H and Shin D: Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11:254–262. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Berköz M, Özkan-Yılmaz F, Özlüer-Hunt A, Krośniak M, Türkmen Ö, Korkmaz D and Keskin S: Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway. Pharmacol Rep. 73:650–663. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mancuso RI, Foglio MA and Olalla Saad ST: Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemother Pharmacol. 87:1–22. 2021. View Article : Google Scholar : PubMed/NCBI |
